

Fecha del CVA

31/10/2019

## Parte A. DATOS PERSONALES

Nombre y Apellidos			
DNI/NIE/Pasaporte		Edad	
Núm. identificación del investigador	Researcher ID		
	Scopus Author ID		
	Código ORCID		

### A.1. Situación profesional actual

Organismo	Universidad de Córdoba		
Dpto. / Centro	Medicina / Universidad de Córdoba		
Dirección			
Teléfono		Correo electrónico	
Categoría profesional	Catedrático	Fecha inicio	2015
Espec. cód. UNESCO	320000 - Ciencias Médicas		
Palabras clave			

### A.2. Formación académica (título, institución, fecha)

Licenciatura/Grado/Doctorado	Universidad	Año
Doctor en Medicina	Universidad de Córdoba	1982
Licenciado en Medicina y Cirugía	Universidad de Córdoba	1979

### A.3. Indicadores generales de calidad de la producción científica

## Parte B. RESUMEN LIBRE DEL CURRÍCULUM

### Parte C. MÉRITOS MÁS RELEVANTES (ordenados por tipología)

#### C.1. Publicaciones

- Artículo científico.** Elez, Elena; et al. 2019. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. *British journal of cancer*. 121-5, pp.378-383. ISSN 1532-1827.
- Artículo científico.** Camps Herrero, C.; et al. 2019. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP) CLINICAL & TRANSLATIONAL ONCOLOGY. SPRINGER INTERNATIONAL PUBLISHING AG. 21-3, pp.380-390. ISSN 1699-048X, ISSN 1699-3055.
- Artículo científico.** Garcia-Foncillas, Jesus; et al. 2018. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer BRITISH JOURNAL OF CANCER. NATURE PUBLISHING GROUP. 119-12, pp.1464-1470. ISSN 0007-0920, ISSN 1532-1827.
- Artículo científico.** Garcia-Alfonso, Pilar; et al. 2018. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial) ONCOLOGIST. WILEY. 23-11, pp.1271-+. ISSN 1083-7159, ISSN 1549-490X.
- Artículo científico.** Aranda, E.; et al. 2018. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. 101, pp.263-272. ISSN 0959-8049, ISSN 1879-0852.
- Artículo científico.** Palomar Munoz, Azahara; et al. 2018. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose [F-18] FDG) in the detection of recurrent ovarian cancer MEDICINA CLINICA. ELSEVIER DOYMA SL. 151-3, pp.97-102. ISSN 0025-7753, ISSN 1578-8989.

- 7 **Artículo científico.** Gravalos, Cristina; et al. 2018. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer CLINICAL COLORECTAL CANCER. CIG MEDIA GROUP, LP. 17-2, pp.E323-E329. ISSN 1533-0028, ISSN 1938-0674.
- 8 **Artículo científico.** Sjoquist, Katrin M.; et al. 2018. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. OXFORD UNIV PRESS INC. 110-6, pp.638-648. ISSN 0027-8874, ISSN 1460-2105.
- 9 **Artículo científico.** Lopez Lopez, R.; et al. 2018. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study CLINICAL & TRANSLATIONAL ONCOLOGY. SPRINGER-VERLAG ITALIA SRL. 20-5, pp.613-618. ISSN 1699-048X, ISSN 1699-3055.
- 10 **Artículo científico.** Irigoyen, Antonio; et al. 2018. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers PLOS ONE. PUBLIC LIBRARY SCIENCE. 13-4. ISSN 1932-6203.
- 11 **Artículo científico.** E Aranda Aguilar; et al. 2018. Value of (18F) FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.Medicine (Baltimore). 97-17.
- 12 **Artículo científico.** Gravalos, Cristina; et al. 2018. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.Clinical colorectal cancer. ISSN 1938-0674.
- 13 **Artículo científico.** Arjona-Sanchez, A.; et al. 2018. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma BMC CANCER. BIOMED CENTRAL LTD. 18. ISSN 1471-2407.
- 14 **Artículo científico.** Alsina, Maria; et al. 2018. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients TARGETED ONCOLOGY. SPRINGER. 13-1, pp.69-78. ISSN 1776-2596, ISSN 1776-260X.
- 15 **Artículo científico.** Abad, A.; et al. 2018. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial ANNALS OF ONCOLOGY. OXFORD UNIV PRESS. 29-2, pp.439-444. ISSN 0923-7534, ISSN 1569-8041.
- 16 **Artículo científico.** Penarando, Jon; et al. 2018. A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer BMC BIOLOGY. BIOMED CENTRAL LTD. 16. ISSN 1741-7007.
- 17 Vivancos, A.; et al. 2019. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.Scientific reports. 9-1, pp.8976. ISSN 2045-2322.
- 18 Carrato, A.; et al. 2019. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).BMC cancer. 19-1, pp.533. ISSN 1471-2407.
- 19 Borrero Palacios, A.; et al. 2019. Author Correction: Combination of KIR2DS4 and FcγRIIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.Scientific reports. 9-1, pp.7706. ISSN 2045-2322.
- 20 Peñarando, J.; Aranda, E.; Rodríguez Ariza, A.2019. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response.Translational research : the journal of laboratory and clinical medicine. ISSN 1878-1810.
- 21 Santos, C.; et al. 2019. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.Annals of oncology : official journal of the European Society for Medical Oncology. ISSN 1569-8041.
- 22 Vidal, J.; et al. 2019. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.Annals of oncology : official journal of the European Society for Medical Oncology. 30-3, pp.439-446. ISSN 1569-8041.

- 23 Reina, R.; et al. 2019. Genome and secretome of *Chondrostereum purpureum* correspond to saprotrophic and phytopathogenic life styles. *PloS one*. 14-3, pp.e0212769. ISSN 1932-6203.

## **C.2. Proyectos**

- 1 Asociación entre inmunidad antitumoral, el sistema renina-angiotensina y la respuesta a terapia antiangiogénica en cáncer colorrectal Instituto de Salud Carlos III. Enrique Aranda Aguilar. (Hospital Universitario Reina Sofía). 01/01/2017-31/12/2019. 98.615 €.
- 2 Polimorfismos de la enzima convertidora de angiotensina para predecir o pronosticar la respuesta al tratamiento antiangiogénico del cáncer Fundación para la innovación y la prospectiva en España. Antonio Rodríguez Ariza. (Hospital Universitario Reina Sofía). 01/02/2015-01/02/2016. 25.000 €.

## **C.3. Contratos**

## **C.4. Patentes**